Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, stab-free way to treat diabetes and obesity.

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has a reputation for being the go-to choice for income-focused investors ...

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

As tough as it may be to do right now, this is a great time to hold your nose and dive in while yields are as high as they are.

Adding narrowband ultraviolet B (UVB) phototherapy to oral treatment with ritlecitinib (Litfulo) enhanced repigmentation in ...

If approved for wide release, the pill, orforglipron, could shake up the booming GLP-1 market by offering an option that's easier to make and store than the injections that are currently available.

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.